Compare TRC & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRC | VOGX |
|---|---|---|
| Founded | 1843 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.4M | 482.8M |
| IPO Year | 1995 | 2026 |
| Metric | TRC | VOGX |
|---|---|---|
| Price | $17.11 | $13.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 123.5K | 74.7K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $37,830,000.00 | N/A |
| Revenue This Year | $10.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $77.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.31 | $12.61 |
| 52 Week High | $21.31 | $38.41 |
| Indicator | TRC | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 34.76 |
| Support Level | $15.87 | N/A |
| Resistance Level | $19.78 | $22.10 |
| Average True Range (ATR) | 0.53 | 2.39 |
| MACD | 0.02 | -0.37 |
| Stochastic Oscillator | 47.50 | 11.02 |
Tejon Ranch Co is a diversified real estate development and agribusiness company. It has six reporting segments: Real Estate - Commercial/Industrial, Multifamily, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.